Advanced Filters
noise

Miami Shores, Florida Clinical Trials

A listing of Miami Shores, Florida clinical trials actively recruiting patient volunteers.

Found 589 clinical trials
J Juan P Alderuccio, MD

Zanubrutinib in Combination With Pola-R-CHP and High-dose Methotrexate in Patients With Secondary CNS Lymphoma

The purpose of this study is to is to determine the effects (good and bad) of Zanubrutinib in Combination with Pola-R-CHP and High-dose Methotrexate in patients with Secondary Central Nervous System (CNS) Lymphoma.

18 years of age All Phase 1
P Patricia Graham, MS, CCRC

Auricular Vagus Nerve Stimulation (aVNS) in Chronic Spinal Cord Injuries (SCI)

The purpose of this research is to test if Auricular Vagal Nerve Stimulation (aVNS) is safe in persons with spinal cord injury (SCI).

18 - 65 years of age All Phase N/A
B Benjamin Spieler, MD

The University of Miami Adapt (UAdapt) Trial

The Miami UAdapt Trial is a non-comparative, risk adapted, parallel, randomized, phase 2 study for patients with favorable-intermediate to very high risk non-metastatic prostate cancer with the primary objective of assessing the efficacy and modulation of response of Lattice Extreme Ablative Dose (LEAD) RT with and without androgen deprivation therapy …

35 - 85 years of age Male Phase 2
I Izidore Lossos, MD

Mosunetuzumab in Patients With Newly Diagnosed Extranodal Marginal Zone Lymphoma

The purpose of this study is to test a new medication called Mosunetuzumab to see if it can help people with Extranodal Marginal Zone Lymphoma (EMZL). This study will include people who have not yet received any treatment for cancer and whose cancer is in stage I-IV. This study will …

18 years of age All Phase 2
D Donna Wheatley

Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors

The objective of this study is to evaluate the safety, tolerability, and efficacy of BL-M07D1 in patients with HER2 expressing advanced tumors.

18 years of age All Phase 1
A Aman Chauhan, MD

SVV-001 With Nivolumab and Ipilimumab in Patients With Poorly Differentiated Neuroendocrine Carcinomas (NEC) or Well-Differentiated High-Grade Neuroendocrine Tumors (NET)

The purpose of this study is to determine: The highest dose of the trial intervention that targets neuroendocrine tumors and is tolerated by patients. The highest frequency of dosing of the trial intervention that targets neuroendocrine tumors and is tolerated by patients. The highest dose and frequency of dosing of …

18 years of age All Phase 1
T Tyler Bartholomew, PhD

Advancing Access to HIV/HCV Testing for People Who Inject Drugs (PWID)

The purpose of this study is to test the effectiveness of the ACCESS strategy: an organizational-level intervention that uses funding and practice facilitation to improve the organizational capacity of syringe services programs (SSPs) to implement routine, opt-out HIV and Hepatitis C (HCV) testing and linkage to care for people who …

18 years of age All Phase N/A
D Dickran Kazandjian, MD

IMMUNOPLANT for Newly Diagnosed Multiple Myeloma

The purpose of this study is to determine whether Linvoseltamab therapy in patients with newly diagnosed multiple myeloma will convert the disease status from minimal residual disease (MRD)-positive to MRD-negative, and increase the length of time that the disease is controlled. The researchers also want to find out the effects …

18 years of age All Phase 2
B Benjamin Spieler, MD

The Miami "EMPIRE" Trial - Eradication of Metastatic Pancreatic Cancer With Immuno-Radiation

The purpose of this study is to assess if radiation therapy (which uses high-energy radiation to damage or destroy cancer cells) combined with immune checkpoint inhibitors (medications that helps the body recognize and attack cancer cells) will be beneficial for patients with metastatic pancreatic ductal adenocarcinoma.

18 years of age All Phase 2
S Stefani Butts, MPH

The Test-to-PrEP Study

To compare the effectiveness of two social network strategies (direct distribution and referral-based distribution) in increasing HIV self-testing (HIVST) completion rates among social network contacts of current Pre-Exposure Prophylaxis (PrEP) clients.

18 years of age All Phase N/A

Simplify language using AI